Effect of lipid lowering agents on lipid profile, blood glucose and Glycated hemoglobin in DM patients

Abstract

Background: lipid lowering agentsare the cornerstone of primary and secondary prevention of cardiovascular disease. As diabetes is an important risk factor for cardiovascular disease and most patients with diabetes would benefit from statin therapy. The aim of the present study was to study the effect of lipid lowering agent on blood glucose, HbA1C and lipid profile among diabetic patients. Methodology:Case control study was conducted in diabetic center at Benghazi city consists of 164 participants with diabetic dyslipidemia, 60 dyslipidemic non-diabetic and 37 healthy control were age and sex matching recruited from diabetic center, cardiac center and volunteers. Data collected was done by using self-constructed questionnaire and analyzed by using mean ± SD and T test was used for statistical differences at α< 0.05. Result:The data collected on 261shown that lipid lowering agent particularly simvastatin has significant effect on lowering FBG, PPBS and HbA1c. The dose of simvastatin has been found have effective role was 20 mg/day. Atorvastatin worked on another side in lowering serum, TG, cholesterol, HDL and VLDL and elevated HDL.Simvastatin was much better working in reduced FBS, PPBS and HbA1C in both types of diabetes while atorvastatin found better outcome for lowering lipid profile and elevated HDL in the type one diabetes mellitus and no differences in the previous parameters have been found among simvastatin have shown great efficiency in reducing FBS, PPBS and HbA1C in T2DM. Conclusion:lipid lowering agents particular simvastatin improved glucose hemostasis and HbA1C while atorvastatin worked significantly in lowering lipid profile and elevated HDL.This data suggested thatsingle dose of statin be given in diabetic patients without dyslipidemia as guideline treatment to reduced risk of diabetic induced CVD. Key words: lipid lowering, Diabetes, FBS, PPBS, HbA1C, healthy control.